|
Surgery on tumors is dangerous and not always foolproof. The
surgeon may not be able to remove all of the patient's cancer, since they could
also take part of the patient's healthy tissue as well. Even though cancerous
cells glow on an MRI , they look just remarkable similar to healthy cells
during operation.

This was the frustrating reality for Dr. Jim Olson, a
pediatric neuro-oncologist. So instead of staying with the status-quo he
gathered a team and created Tumor Paint, a product designed to illuminate
cancer cells in the body, helping surgeons distinguish them from healthy
tissue.
Olson found a scientist at the University of Alabama at
Birmingham who was using venom from an Israeli deathstalker scorpion to target
brain tumors. Since the venom attached to the cancerous cells without affecting
the healthy tissue, Olson proposed that attaching a "molecular flashlight"
would make the tumor cells stand out during surgery.
Backed by funding (raised by a parent of a cancer
patient), Olson and his team were able to identify a small protein or peptide
in the scorpion's venom to produce Tumor Paint. To test their product they grew
a brain tumor on a mouse's back and injected it with the "paint." Within an
hour the cancer was lighting up!
Tumor Paint is 500 times more sensitive than an MRI and
works on all types of cancers.
With this success Olson founded Blaze Bioscience to run
human clinical trials and commercialize the product. The biotech company is on
track to start enrollment for trials in Australia in December, CEO Heather
Franklin said. Blaze Biotech has a focus
on creating drugs from things in nature to better fight disease.
"We're creating drug candidates ... that could
fundamentally change the world," Olson says. "We're throwing motives
of profit or biotech building to the wind. Let's do what's right for the
greatest number of people."
Read more about this project here.
|